Bookbuilding IPO | ₹1,514 Cr | Listed at BSE, NSE
Glenmark Life Sciences IPO is a book build issue of ₹1,513.60 crores. The issue is a combination of fresh issue of 1.47 crore shares aggregating to ₹1,060.00 crores and offer for sale of 0.63 crore shares aggregating to ₹453.60 crores.
Glenmark Life Sciences IPO bidding started from Jul 27, 2021 and ended on Jul 29, 2021. The allotment for Glenmark Life Sciences IPO was finalized on Aug 3, 2021. The shares got listed on BSE, NSE on Aug 6, 2021.
Glenmark Life Sciences IPO price band is set at ₹720 per share. The lot size for an application is 20. The minimum amount of investment required by an retail is ₹14,400 (20 shares) (based on upper price). The lot size investment for sNII is 14 lots (280 shares), amounting to ₹2,01,600, and for bNII, it is 70 lots (1,400 shares), amounting to ₹10,08,000.
BOFA Securities India Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Glenmark Life Sciences IPO RHP for detailed Information.
IPO Open
Tue, Jul 27, 2021
IPO Close
Thu, Jul 29, 2021
Issue Price
₹720 per share
Market Cap (Pre-IPO)
To be declared
| IPO Date | 27 to 29 Jul, 2021 |
| Listed on | Fri, Aug 6, 2021 |
| Face Value | ₹2 per share |
| Price Band | ₹695 to ₹720 |
| Issue Price | ₹720 per share |
| Lot Size | 20 Shares |
| Sale Type | Fresh Capital & OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,10,22,222 shares (agg. up to ₹1,514 Cr) |
| Fresh Issue | 1,47,22,222 shares (agg. up to ₹1,060 Cr) |
| Offer for Sale | 63,00,000 shares of ₹2 (agg. up to ₹454 Cr) |
| Share Holding Pre Issue | 10,78,04,950 shares |
| Share Holding Post Issue | 12,25,27,172 shares |
| BSE Script Code / NSE Symbol | 543322 / ALIVUS |
| ISIN | INE03Q201024 |
Glenmark Life Sciences IPO offers total 2,10,22,222 shares. Out of which 1,05,11,110 (50.00%) allocated to QIB, 42,04,450 (20.00%) allocated to QIB (Ex- Anchor), 31,53,334 (15.00%) allocated to NII 73,57,778 (35.00%) allocated to RII and 63,06,660 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 1,05,11,110 (50.00%) | NA |
| − Anchor Investor Shares Offered | 63,06,660 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 42,04,450 (20.00%) | NA |
| NII (HNI) Shares Offered | 31,53,334 (15.00%) | NA |
| Retail Shares Offered | 73,57,778 (35.00%) | 3,67,888 |
| Total Shares Offered | 2,10,22,222 (100.00%) |
Investors can bid for a minimum of 20 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,400 |
| Retail (Max) | 13 | 260 | ₹1,87,200 |
| S-HNI (Min) | 14 | 280 | ₹2,01,600 |
| S-HNI (Max) | 69 | 1,380 | ₹9,93,600 |
| B-HNI (Min) | 70 | 1,400 | ₹10,08,000 |
Glenmark Life Sciences IPO raises ₹454.08 crore from anchor investors. Glenmark Life Sciences IPO Anchor bid date is July 26, 2021.
📝 Anchor Investors Letter (PDF)
| Bid Date | Mon, Jul 26, 2021 |
| Shares Offered | 63,06,660 |
| Anchor Portion (₹ Cr.) | 454.08 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Sep 2, 2021 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, Nov 1, 2021 |
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive strengths
| Period Ended |
|---|
| Amount in ₹ Crore |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018 | 800.00 |
| 2 | Funding the capital expenditure requirements | 152.76 |
| 3 | General corporate purposes | 57.68 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Managers fees | 40.84 |
| 2 | Commission/processing fee for SCSBs, Sponsor Bank and Bankers to the Offer. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 9.24 |
| 3 | Fees payable to the Registrar to the Offer | 0.42 |
| 4 | Fees payable to the other advisors to the Offer | 2.38 |
| 5 | Listing fees, SEBI filing fees, BSE and NSE processing fees, book building software fees and other regulatory expenses | 5.55 |
| 6 | Printing and stationery | 1.91 |
| 7 | Advertising and marketing expenses | 5.10 |
| 8 | Fee payable to legal counsels | 4.03 |
| 9 | Miscellaneous | 2.37 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹720.00 | ₹720.00 |
| Open | ₹751.10 | ₹750.00 |
| Low | ₹737.35 | ₹738.00 |
| High | ₹799.95 | ₹799.00 |
| Last Trade | ₹748.20 | ₹748.50 |
Lead Manager Reports
Glenmark Life Sciences IPO is a main-board IPO of 2,10,22,222 equity shares of the face value of ₹2 aggregating up to ₹1,514 Crores. The issue is priced at ₹720 per share. The minimum order quantity is 20.
The IPO opens on Tue, Jul 27, 2021, and closes on Thu, Jul 29, 2021.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Glenmark Life Sciences IPO using UPI as a payment gateway. Zerodha customers can apply in Glenmark Life Sciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Glenmark Life Sciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Glenmark Life Sciences IPO opens on Tue, Jul 27, 2021 and closes on Thu, Jul 29, 2021.
Glenmark Life Sciences IPO lot size is 20, and the minimum amount required for application is ₹14,400.
You can apply in Glenmark Life Sciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Glenmark Life Sciences IPO will be done on Tuesday, August 3, 2021, and the allotted shares will be credited to your demat account by Thu, Aug 5, 2021. Check the Glenmark Life Sciences IPO allotment status.
The Glenmark Life Sciences IPO listing date is on Fri, Aug 6, 2021.
